JPH06256170A - Coated pharmaceutical preparation - Google Patents
Coated pharmaceutical preparationInfo
- Publication number
- JPH06256170A JPH06256170A JP5063023A JP6302393A JPH06256170A JP H06256170 A JPH06256170 A JP H06256170A JP 5063023 A JP5063023 A JP 5063023A JP 6302393 A JP6302393 A JP 6302393A JP H06256170 A JPH06256170 A JP H06256170A
- Authority
- JP
- Japan
- Prior art keywords
- coating layer
- substance
- active substance
- pharmaceutically active
- coated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、内服用固形製剤に関
し、より詳細には、医薬活性物質の不快な味や臭いをマ
スキングした被覆製剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a solid preparation for internal use, and more particularly to a coated preparation in which the unpleasant taste and odor of a pharmaceutically active substance are masked.
【0002】[0002]
【従来の技術】従来より、医薬活性物質に不快な味や臭
いがある場合には、その医薬活性物質を含有する内核表
面に、アミノアルキルメタアクリレート コポリマー
E、ポリビニルアセタールジエチルアミノアセテート等
の胃溶性の材料すなわち酸性溶液に溶解する材料をコー
ティングしていた。しかし、胃溶性の材料は、医薬活性
物質と配合変化し易いため、被覆製剤の経時的な着色変
化を加速することがある。また、胃溶性の材料を用いた
被覆製剤は、患者の消化管内溶液のpHが、食事の前後
あるいは年齢等により大きく変動するので、医薬活性物
質の放出が一定せず、その薬理効果にばらつきが生じ易
い。2. Description of the Related Art Conventionally, when a pharmaceutically active substance has an unpleasant taste or odor, a gastric-soluble substance such as aminoalkyl methacrylate copolymer E, polyvinyl acetal diethylaminoacetate or the like is formed on the surface of the inner core containing the pharmaceutically active substance. The material was coated with a material that dissolves in the acidic solution. However, since the gastric-soluble material is likely to change the compounding with the pharmaceutically active substance, the coloration change of the coated preparation with time may be accelerated. In addition, since the pH of the gastrointestinal tract solution of a patient in the coated preparation using a gastric-soluble material varies greatly depending on before and after meals, age, etc., the release of the pharmaceutically active substance is not constant and the pharmacological effect varies. It is easy to occur.
【0003】胃溶性の材料の持つ欠点を改善する研究と
しては、一つには水溶性の材料に疎水性物質(ワックス
類、高級脂肪酸等)を添加した被覆製剤が提案されてい
る(特開昭53−139717号公報)。また一方で
は、熱溶融性物質を材料としたもの及び水不溶性のアク
リル系重合体(アミノアルキルメタアクリレート コポ
リマーRS)を用いた被覆製剤が提案されている(特開
平4−217913号公報、特開平2−42967号公
報、特開昭63−27423号公報、特開平2−497
21公報)。しかしながら、開示されたいずれの被覆製
剤も、服用し易く、しかも医薬活性物質の放出性と製剤
学的安定性に優れたものとはいい難い。As a study for improving the drawbacks of the gastric-soluble material, one of the proposals is a coated preparation in which a hydrophobic substance (wax, higher fatty acid, etc.) is added to a water-soluble material (Japanese Patent Application Laid-Open No. 2000-242242). 53-139717). On the other hand, a coating preparation using a heat-meltable material as a material and a water-insoluble acrylic polymer (aminoalkylmethacrylate copolymer RS) has been proposed (JP-A-4-217913, JP-A-4-217913). JP-A-2-42967, JP-A-63-27423, JP-A-2-497.
21). However, it is difficult to say that any of the disclosed coated preparations is easy to take and is excellent in the release of the pharmaceutically active substance and the pharmaceutical stability.
【0004】[0004]
【発明が解決しようとする課題】本発明の課題は、医薬
活性物質の味や臭いを効果的にマスキングでき、したが
って服用し易く、しかも医薬活性物質の放出性と製剤学
的安定性に優れた被覆製剤を提供することにある。The object of the present invention is to effectively mask the taste and odor of a pharmaceutically active substance, and therefore, it is easy to take, and the release of the pharmaceutically active substance and the pharmaceutical stability are excellent. It is to provide a coated preparation.
【0005】[0005]
【課題を解決するための手段】本発明者らは、医薬活性
物質の味や臭いのマスキングに利用できる種々の添加剤
の中から、矯味を目的とする矯味コーティング層と防臭
を目的とする防臭コーティング層のそれぞれに適切な材
料を選択した。さらに本発明者らは前記材料を用いて医
薬活性物質を含有する内核表面に矯味コーティング層を
施し、さらに、矯味コーティング層の外層に防臭コーテ
ィング層を施すことによって、上記課題を解決する本発
明を完成した。即ち、本発明は、内服用固形製剤におい
て、医薬活性物質を含有する内核表面に、アミノアルキ
ルメタアクリレート コポリマーRSを用いたコーティ
ング層を施し、さらに、前記コーティング層の外層に、
疎水性物質と水不溶性の無機質のみからなるコーティン
グ層を施してなる被覆製剤を提供するものである。[Means for Solving the Problems] The present inventors have found that, from among various additives that can be used for masking the taste and odor of pharmaceutically active substances, a taste masking coating layer for the purpose of taste masking and a deodorant for the purpose of deodorizing. Appropriate materials were chosen for each of the coating layers. Furthermore, the present inventors solve the above problems by applying a taste masking coating layer to the surface of the inner core containing a pharmaceutically active substance using the above material, and further applying an odor preventing coating layer to the outer layer of the taste masking coating layer. completed. That is, the present invention, in a solid preparation for internal use, a coating layer using an aminoalkyl methacrylate copolymer RS is applied to the inner core surface containing a pharmaceutically active substance, and further, an outer layer of the coating layer,
It is intended to provide a coated preparation having a coating layer composed of only a hydrophobic substance and a water-insoluble inorganic substance.
【0006】本発明者らは、矯味コーティング層の材料
を選択するにあたり、本発明の構成に含まれるアミノア
ルキルメタアクリレート コポリマーRS(日本薬局方
外医薬成分規格第二部収載品)が医薬活性物質と配合変
化することが少ない材料であることを見いだした。ま
た、アミノアルキルメタアクリレート コポリマーRS
は、pHに依存しない溶解特性を有しているため、消化
管内溶液のpH変動に影響されることなく医薬活性物質
を放出する。ところが、アミノアルキルメタアクリレー
ト コポリマーRSは、徐放性製剤に用いられている水
に不溶性の材料であり、医薬活性物質の放出を遅延させ
る特性を有している。そこで、本発明者らは、矯味コー
ティング層にアミノアルキルメタアクリレート コポリ
マーRS、疎水性物質及び水不溶性ではあるがはっ水性
を示さない無機質をバランス良く配合することで、医薬
活性物質を速やかに放出するよう工夫した。さらに、医
薬活性物質及びアミノアルキルメタアクリレート コポ
リマーRSをはじめとするアクリル系重合体から経時的
に発生する異臭をマスキングするための防臭コーティン
グ層には、はっ水性を示さない水不溶性の無機質が配合
されており、ワックス類を材料とした顆粒剤や細粒剤の
被覆製剤に見られがちな服用しずらい欠点すなわち表面
がはっ水性であることから口内で凝集してしまう特性を
改善している。In selecting the material for the taste masking coating layer, the present inventors selected the aminoalkyl methacrylate copolymer RS (listed in Part II of the Japanese Pharmacopoeia Standard for Pharmaceutical Ingredients) included in the constitution of the present invention as a pharmaceutically active substance. It was found that the material has a small change in composition. In addition, aminoalkyl methacrylate copolymer RS
Has a pH-independent dissolution property, and thus releases the pharmaceutically active substance without being affected by the pH fluctuation of the solution in the digestive tract. However, the aminoalkyl methacrylate copolymer RS is a water-insoluble material used in sustained-release preparations, and has the property of delaying the release of pharmaceutically active substances. Therefore, the present inventors rapidly release a pharmaceutically active substance by blending the taste masking coating layer with aminoalkylmethacrylate copolymer RS, a hydrophobic substance, and a water-insoluble but non-water-repellent inorganic substance in a well-balanced manner. I devised to do it. Further, a water-insoluble inorganic substance that does not exhibit water repellency is blended in the deodorant coating layer for masking the offensive odor generated with time from the pharmaceutically active substance and the acrylic polymer such as aminoalkyl methacrylate copolymer RS. It is difficult to take, which is the tendency to be seen in coated preparations of granules and fine granules made of waxes, that is, the surface is water repellent, which improves the property of aggregating in the mouth. There is.
【0007】本発明のより好ましい実施態様として、例
えば、前記製剤中の医薬活性物質がアミノ酸、アミノ酸
塩、アミノ酸誘導体及びペプチドから選ばれた1種又は
2種以上である被覆製剤を挙げることができる。前記ア
ミノ酸、アミノ酸塩としては、各種の必須アミノ酸及び
非必須アミノ酸、アミノ酸誘導体としては、タウリン等
の含硫アミノ酸誘導体を挙げることができる。ペプチド
としては、合成によるオリゴペプチド、ペプチドホルモ
ン、動植物蛋白の部分加水分解物等が挙げられる。As a more preferred embodiment of the present invention, there can be mentioned, for example, a coated preparation in which the pharmaceutically active substance in the preparation is one or more selected from amino acids, amino acid salts, amino acid derivatives and peptides. . Examples of the amino acids and amino acid salts include various essential and non-essential amino acids, and examples of the amino acid derivatives include sulfur-containing amino acid derivatives such as taurine. Examples of the peptide include synthetic oligopeptides, peptide hormones, partial hydrolysates of animal and plant proteins, and the like.
【0008】上記アミノアルキルメタアクリレート コ
ポリマーRSとしては市販のオイドラギットRS(レー
ム・ファーマ社(ドイツ)製)が好適に使用できる。上
記疎水性物質としては、固形ワックス類すなわち油脂、
ロウ、炭化水素、高級脂肪酸、高級脂肪酸アルコール、
高級脂肪酸エステル及びヒドロキシ高級脂肪酸エステル
が挙げられる。油脂の中でも硬化植物油(硬化ナタネ
油、硬化ヒマシ油、硬化ヤシ油等)、流動パラフィン、
天然ロウ等が好的に使用できる。これらの疎水性物質
は、一種のみを用いてもよいが、2種以上適宜混合して
使用してもよい。特に、固体状と液状の疎水性物質を併
用することにより望ましい特性をもつコーティング層が
得られる。疎水性物質を併用する場合のより好ましい例
としては、硬化植物油と流動パラフィンの組合せが挙げ
られる。矯味コーティング層中、前記疎水性物質の配合
量としては、5〜60重量%が好ましく、より好ましく
は30〜50重量%である。また、防臭コーティング層
中の疎水性物質の配合量としては、5〜70重量%、よ
り好ましくは40〜60重量%である。As the above aminoalkyl methacrylate copolymer RS, commercially available Eudragit RS (manufactured by Reem Pharma (Germany)) can be preferably used. As the hydrophobic substance, solid waxes, that is, fats and oils,
Wax, hydrocarbon, higher fatty acid, higher fatty acid alcohol,
Examples include higher fatty acid esters and hydroxy higher fatty acid esters. Among the oils and fats, hydrogenated vegetable oil (hardened rapeseed oil, hardened castor oil, hardened coconut oil, etc.), liquid paraffin,
Natural wax etc. can be used conveniently. Only one kind of these hydrophobic substances may be used, or two or more kinds thereof may be appropriately mixed and used. In particular, by using a solid substance and a liquid hydrophobic substance together, a coating layer having desired properties can be obtained. A more preferable example of the combined use of a hydrophobic substance is a combination of hydrogenated vegetable oil and liquid paraffin. The content of the hydrophobic substance in the taste masking coating layer is preferably 5 to 60% by weight, more preferably 30 to 50% by weight. The content of the hydrophobic substance in the deodorant coating layer is 5 to 70% by weight, more preferably 40 to 60% by weight.
【0009】上記水不溶性の無機質としては、タルク、
含水二酸化ケイ素、酸化チタン、軽質無水ケイ酸、合成
ケイ酸マグネシウム、乾燥水酸化アルミニュウムゲル、
沈降炭酸カルシウム及び硫酸カルシウムが挙げられる。
中でも、タルク又は含水二酸化ケイ素が特に好ましい。
矯味コーティング組成中、水不溶性の無機質の配合量と
しては、5〜60重量%が好ましく、より好ましくは3
0〜50重量%である。また、防臭コーティング層中の
水不溶性の無機質の配合量としては、5〜70重量%、
より好ましくは40〜60重量%である。The water-insoluble inorganic substances include talc,
Hydrous silicon dioxide, titanium oxide, light anhydrous silicic acid, synthetic magnesium silicate, dried aluminum hydroxide gel,
Included are precipitated calcium carbonate and calcium sulfate.
Among them, talc or hydrous silicon dioxide is particularly preferable.
The content of the water-insoluble inorganic substance in the taste masking coating composition is preferably 5 to 60% by weight, more preferably 3% by weight.
It is 0 to 50% by weight. The amount of the water-insoluble inorganic compound contained in the deodorant coating layer is 5 to 70% by weight,
More preferably, it is 40 to 60% by weight.
【0010】上記医薬活性物質としては、栄養補給を目
的としたアミノ酸組成物、各種の病態別アミノ酸組成物
である肝不全用アミノ酸組成物、腎不全用アミノ酸組成
物、癌用アミノ酸組成物及び分岐鎖アミノ酸組成物等が
挙げられる。The above-mentioned pharmaceutically active substances include amino acid compositions for the purpose of nutritional supplementation, amino acid compositions for liver failure, amino acid compositions for renal failure, amino acid compositions for cancer, and branches which are amino acid compositions according to various pathological conditions. Chain amino acid compositions and the like.
【0011】[0011]
【作用】本発明の被覆製剤は、矯味コーティング層の材
料として医薬活性物質と配合変化することが少なく、ま
た、pHに依存しない溶解性を有しているアミノアルキ
ルメタアクリレート コポリマーRSを使用している。
従って、本発明の被覆製剤は、医薬活性物質の放出性の
ばらつきが少なく、また経時的な着色変化、溶解特性の
品質劣化が少ない。さらに、本発明の被覆製剤の最外層
には、内核及びアミノアルキルメタアクリレート コポ
リマーRSから生じる不快臭をマスキングする防臭コー
ティング層が施されており、矯味効果のみならず優れた
防臭効果を有している。以下に実施例と試験例を示し、
より具体的に本発明を説明する。The coated preparation of the present invention uses the aminoalkylmethacrylate copolymer RS, which has a low pH-dependent solubility as a material for the taste masking layer, and which does not undergo a compounding change with the pharmaceutically active substance. There is.
Therefore, the coated preparation of the present invention has less variation in the release property of the pharmaceutically active substance, less color change over time, and less deterioration in the dissolution characteristics. Furthermore, the outermost layer of the coated preparation of the present invention is provided with an odor preventive coating layer that masks the unpleasant odor generated from the inner core and the aminoalkyl methacrylate copolymer RS, and has an excellent odor preventive effect as well as a taste masking effect. There is. Examples and test examples are shown below,
The present invention will be described more specifically.
【0012】[0012]
実施例1 表1に示した重量のA群、B群、C群のアミノ酸を群毎
に混合し、さらにヒドロキシプロピルセルロースH型
(日本曹達製)を、A群混合物に50g(1重量%)、
B群混合物に39g(1.5重量%)、C群混合物に3
6g(1.5重量%)加えてそれぞれ混合した。これら
の混合物をそれぞれにエタノール・水混液を適量加えて
練合し、押しだし造粒機にて造粒、整粒機にて整粒し乾
燥した。得られた各群の乾燥粒状物(顆粒)を12〜4
2メッシュの粒径を有するように分級し、表2に示した
組成をもつ矯味コーティング層を、前記顆粒の表面にそ
の5重量%被覆し、さらに、表3に示す組成をもつ防臭
コーティング層を矯味コーティング層の表面にその4重
量%被覆した。各群の顆粒を、A群、B群、C群のアミ
ノ酸重量比が50:26:24になるように混合し、ア
ミノ酸含有顆粒の被覆製剤を得た。Example 1 Amino acids of Group A, Group B, and Group C having the weights shown in Table 1 were mixed for each group, and 50 g (1% by weight) of hydroxypropylcellulose H type (manufactured by Nippon Soda) was added to the Group A mixture. ,
39 g (1.5% by weight) in group B mixture, 3 in group C mixture
6g (1.5wt%) was added and mixed respectively. An appropriate amount of a mixture of ethanol and water was added to each of these mixtures, and the mixture was kneaded, granulated by an extrusion granulator, granulated by a granulator and dried. The resulting dried granules (granules) of each group are 12 to 4
The granules were classified so as to have a particle size of 2 mesh, 5% by weight of the taste masking coating layer having the composition shown in Table 2 was coated on the surface of the granules, and the deodorant coating layer having the composition shown in Table 3 was further prepared. The surface of the taste masking coating layer was coated with 4% by weight thereof. The granules of each group were mixed so that the weight ratio of amino acids of group A, group B and group C was 50:26:24 to obtain a coated preparation of amino acid-containing granules.
【0013】[0013]
【表1】 [Table 1]
【0014】[0014]
【表2】 [Table 2]
【0015】[0015]
【表3】 [Table 3]
【0016】実施例2 L−アルギニン250g、タルク1g、含水二酸化ケイ
素1gを混合し、打錠機(コレクト12HUK 菊水製
作所製)にて外径8.5mm、重量約252mgの素錠
を製錠した。この素錠の表面に、表2に示した組成をも
つ矯味コーティング層を素錠重量の4重量%被覆した。
さらに、表3に示す組成をもつ防臭コーティング層を前
記矯味コーティング層の表面に素錠の重量の3重量%被
覆しL−アルギニン含有の被覆錠剤を得た。Example 2 L-Arginine (250 g), talc (1 g) and hydrous silicon dioxide (1 g) were mixed, and a plain tablet having an outer diameter of 8.5 mm and a weight of about 252 mg was tabletted with a tableting machine (Correct 12HUK, manufactured by Kikusui Seisakusho). . The surface of this plain tablet was coated with a flavoring coating layer having the composition shown in Table 2 at 4% by weight of the plain tablet weight.
Further, an odor preventing coating layer having a composition shown in Table 3 was coated on the surface of the taste masking coating layer in an amount of 3% by weight based on the weight of the uncoated tablets to obtain L-arginine-containing coated tablets.
【0017】次に、試験用のアミノ酸含有顆粒の被覆製
剤を調製した。 比較製剤 実施例1の矯味コーティング層及び防臭コーティング層
の代わりに表4に示す材料を用いて被覆した他は、実施
例1と同様にして3種類の比較製剤(比較製剤1,2,
3)を得た。また、実施例1の製剤において、防臭コー
ティングを施さない他は、実施例1と同様にして比較製
剤4を得た。Then, a coated preparation of amino acid-containing granules for testing was prepared. Comparative Formulation Three types of comparative formulations (Comparative Formulations 1, 2, and 3) were prepared in the same manner as in Example 1 except that the materials shown in Table 4 were used instead of the taste masking layer and the deodorant coating layer of Example 1.
3) was obtained. Further, Comparative Formulation 4 was obtained in the same manner as in Example 1 except that the deodorant coating was not applied to the formulation of Example 1.
【0018】[0018]
【表4】 [Table 4]
【0019】試験例1 着色変化 実施例1及び3種類の比較製剤(比較製剤1,2,3)
をそれぞれガラス瓶に入れ密栓した後60℃の恒温槽内
に保存して、経時的な黄変度(Δb)を色差計(シグマ
80型 日本電色工業社製)で測定した。その測定結果
を図1に示した。Test Example 1 Color Change Example 1 and 3 types of comparative formulations (Comparative formulations 1, 2, 3)
Each was placed in a glass bottle and sealed tightly, and then stored in a constant temperature bath at 60 ° C., and the yellowing degree (Δb) over time was measured with a color difference meter (Sigma 80 type manufactured by Nippon Denshoku Industries Co., Ltd.). The measurement result is shown in FIG.
【0020】試験例2 溶出性 表1に示した各種のアミノ酸のなかで、最も溶出のおそ
いL−チロジンを指標として、実施例1の本発明被覆製
剤並びに3種類の比較製剤(比較製剤1,2,3)の溶
出性を比較した。溶出性の比較は、pHの異なった3種
類の試験液(pH1.2、4.0、6.9)を用い、溶
出試験は日本薬局方溶出試験第2法パドル法に準じた方
法で行った。各被検物質4.44gをそれぞれ試験液に
投入後、30分経過したときのL−チロジン溶出率を液
体クロマトグラフ法により測定し、その測定結果を表5
に示した。試験の結果、実施例1の本発明被覆製剤は、
試験液のpHの違いにより溶出性が変化する比較製剤2
及び比較製剤3とは異なり、いずれの試験液でも高い溶
出率を示した。従って、本発明の被覆製剤は、水溶性の
材料を用いた比較製剤1と同様に消化管内溶液のpHに
依存することなく医薬活性物質を放出することが明らか
となった。Test Example 2 Elutability Among the various amino acids shown in Table 1, the most eluting l-tyrosine was used as an index, and the coated preparation of the present invention of Example 1 and three types of comparative preparations (Comparative Preparation 1, The elution properties of 2, 3) were compared. For comparison of dissolution properties, three types of test liquids with different pH (pH 1.2, 4.0, 6.9) were used, and the dissolution test was conducted according to the Japanese Pharmacopoeia Dissolution Test Method 2 Paddle Method. It was After each test substance (4.44 g) was added to the test solution, the elution rate of L-tyrosine after 30 minutes was measured by a liquid chromatography method, and the measurement results are shown in Table 5.
It was shown to. As a result of the test, the coated preparation of the present invention of Example 1 was
Comparative preparation 2 whose dissolution changes depending on the pH of the test solution 2
Also, unlike Comparative Preparation 3, all test solutions showed a high dissolution rate. Therefore, it was revealed that the coated preparation of the present invention releases the pharmaceutically active substance without depending on the pH of the solution in the digestive tract, like the comparative preparation 1 using the water-soluble material.
【0021】[0021]
【表5】 [Table 5]
【0022】試験例3 溶出速度 実施例1の本発明被覆製剤を被検物質として、試験液を
水とした他は、試験例2と同様にして、被検物質投入
後、5分、10分、15分、20分、25分、30分、
及び1時間経過したときのL−チロジンの溶出率を測定
し、その結果を図2に示した。試験の結果、本発明の被
覆製剤は、徐放性製剤に用いられている水不溶性の材料
であるアミノアルキルメタアクリレート コポリマーR
Sを矯味コーティング層に含んでいるにもかかわらず、
疎水性物質及び水不溶性ではあるがはっ水性を示さない
無機質をバランス良く配合することで、服用後速やかに
医薬活性物質を放出することが判った。Test Example 3 Elution Rate 5 minutes, 10 minutes after the test substance was charged in the same manner as in Test Example 2 except that the coated preparation of the present invention of Example 1 was used as the test substance and the test liquid was water. , 15 minutes, 20 minutes, 25 minutes, 30 minutes,
And the elution rate of L-tyrosine after 1 hour was measured, and the results are shown in FIG. As a result of the test, the coated preparation of the present invention showed that the water-insoluble material used in the sustained-release preparation was aminoalkyl methacrylate copolymer R.
Even though S is included in the taste masking coating layer,
It has been found that by mixing a hydrophobic substance and an inorganic substance that is water-insoluble but does not exhibit water repellency in a well-balanced manner, the pharmaceutically active substance is released promptly after administration.
【0023】試験例4 官能試験 実施例1の本発明被覆製剤及び比較製剤4を被検物質と
して、それぞれ4.44gずつ分包包装し、60℃の恒
温器中に7日間保存した。加温虐待後、各被検物質4.
44gを、それぞれ8名のパネラーの口腔中に含ませて
悪味、異臭の有無を評価し、その結果を表6に示した。
試験の結果、本発明被覆製剤は、8名のパネラー全員が
その服用に際し悪味、異臭ともに感じなかったことから
服用し易い製剤であることが判った。防臭コーティング
層を施さなかった比較製剤4は、悪味は感じられなかっ
たものの、全パネラーが異臭を感じると評価し、防臭コ
ーティング層の防臭効果が認められた。Test Example 4 Sensory Test The coated preparation of the present invention and Comparative Preparation 4 of Example 1 were used as test substances, and 4.44 g of each was packaged in a package and stored in a thermostat at 60 ° C. for 7 days. After the abuse by heating, each test substance 4.
Eighty-four panelists were allowed to each contain 44 g of the oral cavity, and the presence or absence of bad taste and offensive odor was evaluated, and the results are shown in Table 6.
As a result of the test, it was found that the coated preparation of the present invention was easy to take because all eight panelists did not feel any bad taste or offensive odor when taking the preparation. Comparative Formulation 4, which did not have the deodorant coating layer, did not have a bad taste, but it was evaluated that all panelists felt an offensive odor, and the deodorant effect of the deodorant coating layer was recognized.
【0024】[0024]
【表6】 [Table 6]
【0025】[0025]
【発明の効果】以上説明したように本発明によれば、医
薬活性物質の味や臭いを効果的にマスキングでき、した
がって服用し易く、しかも医薬活性物質の放出性と製剤
学的安定性に優れた内服用固形製剤が提供できる。Industrial Applicability As described above, according to the present invention, the taste and odor of a pharmaceutically active substance can be effectively masked, and therefore, it is easy to take and the release of the pharmaceutically active substance and the pharmaceutical stability are excellent. A solid preparation for oral administration can be provided.
【図1】経時的な着色変化を示した図である。FIG. 1 is a diagram showing a color change over time.
【図2】溶出試験の結果を示した図である。FIG. 2 is a diagram showing the results of a dissolution test.
Claims (2)
含有する内核表面に、アミノアルキルメタアクリレート
コポリマーRSを用いたコーティング層を施し、さら
に、前記コーティング層の外層に、疎水性物質と水不溶
性の無機質のみからなるコーティング層を施してなるこ
とを特徴とする被覆製剤。1. A solid preparation for internal use, wherein a coating layer using an aminoalkyl methacrylate copolymer RS is applied to the inner core surface containing a pharmaceutically active substance, and a hydrophobic substance and water-insoluble substance are further applied to the outer layer of the coating layer. A coated preparation characterized by comprising a coating layer consisting of only the above-mentioned inorganic substances.
ミノ酸誘導体及びペプチドから選ばれた1種又は2種以
上である請求項1記載の被覆製剤。2. The coated preparation according to claim 1, wherein the pharmaceutically active substance is one or more selected from amino acids, amino acid salts, amino acid derivatives and peptides.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP06302393A JP3472317B2 (en) | 1993-02-26 | 1993-02-26 | Coated preparation |
| CN 94101348 CN1097595A (en) | 1993-02-26 | 1994-02-16 | Coated pharmaceutical preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP06302393A JP3472317B2 (en) | 1993-02-26 | 1993-02-26 | Coated preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH06256170A true JPH06256170A (en) | 1994-09-13 |
| JP3472317B2 JP3472317B2 (en) | 2003-12-02 |
Family
ID=13217318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP06302393A Expired - Fee Related JP3472317B2 (en) | 1993-02-26 | 1993-02-26 | Coated preparation |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP3472317B2 (en) |
| CN (1) | CN1097595A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078171A1 (en) * | 2003-03-06 | 2004-09-16 | Kyowa Hakko Kogyo Co., Ltd. | Tablet containing water-absorbing amino acid |
| US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
| US7906112B2 (en) | 2003-12-19 | 2011-03-15 | The Procter & Gamble Company | Canine probiotic Lactobacilli |
| US8168170B2 (en) | 2002-10-03 | 2012-05-01 | The Procter And Gamble Company | Compositions having an inner core and at least three surrounding layers |
| US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
| US8900569B2 (en) | 2003-12-19 | 2014-12-02 | The Iams Company | Method of treating diarrhea in a canine |
| US9415083B2 (en) | 2004-05-10 | 2016-08-16 | Mars, Incorporated | Method for decreasing inflammation and stress in a mammal |
| US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
| US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
-
1993
- 1993-02-26 JP JP06302393A patent/JP3472317B2/en not_active Expired - Fee Related
-
1994
- 1994-02-16 CN CN 94101348 patent/CN1097595A/en active Pending
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168170B2 (en) | 2002-10-03 | 2012-05-01 | The Procter And Gamble Company | Compositions having an inner core and at least three surrounding layers |
| JPWO2004078171A1 (en) * | 2003-03-06 | 2006-06-08 | 協和醗酵工業株式会社 | Water-absorbing amino acid-containing tablets |
| WO2004078171A1 (en) * | 2003-03-06 | 2004-09-16 | Kyowa Hakko Kogyo Co., Ltd. | Tablet containing water-absorbing amino acid |
| US8894991B2 (en) | 2003-12-19 | 2014-11-25 | The Iams Company | Canine probiotic Lactobacilli |
| US7906112B2 (en) | 2003-12-19 | 2011-03-15 | The Procter & Gamble Company | Canine probiotic Lactobacilli |
| US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
| US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
| US8900569B2 (en) | 2003-12-19 | 2014-12-02 | The Iams Company | Method of treating diarrhea in a canine |
| US9821015B2 (en) | 2003-12-19 | 2017-11-21 | Mars, Incorporated | Methods of use of probiotic bifidobacteria for companion animals |
| US9415083B2 (en) | 2004-05-10 | 2016-08-16 | Mars, Incorporated | Method for decreasing inflammation and stress in a mammal |
| US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
| US10709156B2 (en) | 2008-07-07 | 2020-07-14 | Mars, Incorporated | Pet supplement and methods of making |
| US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1097595A (en) | 1995-01-25 |
| JP3472317B2 (en) | 2003-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5382601A (en) | Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof | |
| AU2003200059B2 (en) | Pharmaceutical pellets comprising tamsulosin and a process for making the same | |
| AU2001255509B2 (en) | Taste masking coating composition | |
| TW420618B (en) | Controlled release-initiation and controlled release-rate pharmaceutical composition | |
| CA2304110C (en) | Theophylline sustained release tablet | |
| RU2246293C2 (en) | Pharmaceutical compositions for oral administration with sustained-releasing active component and masking taste | |
| JP5627854B2 (en) | Gastric reflux resistant dosage form | |
| CA2625554C (en) | Enteric soft capsule comprising valproic acid | |
| JPH05221854A (en) | Controlling release tablet containing watersoluble chemical | |
| ME00520B (en) | Levodopa / carbidopa / entacapone pharmaceutical preparation | |
| JPS62120316A (en) | Tablet composition with controlled drug release | |
| JPH02221219A (en) | Adhesive tablet | |
| JPS6327439A (en) | Sustained release medicinal effect preparation | |
| CA2250318C (en) | Sustained-release metal valproate tablets | |
| JPH06256170A (en) | Coated pharmaceutical preparation | |
| PT571973E (en) | DELAYED LIBERTACAO SODIUM VALPROATE TABLETS | |
| KR101647869B1 (en) | Powdery or granulated composition comprising a copolymer, a dicarboxylic acid and a fatty monocarboxylic acid | |
| KR20120086689A (en) | Film-coated tablet which is suppressed in discoloration and odor | |
| JP2002316928A (en) | Coated tablets and methods to prevent peeling of coated tablets | |
| MX2011002400A (en) | Pharmaceutical solid preparation having active ingredients separated by boundary therein. | |
| HRP960598A2 (en) | Rapid release tablet comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet | |
| Obeidat et al. | Preparation and evaluation of ternary polymeric blends for controlled release matrices containing weakly basic model drug | |
| US3629394A (en) | Pleasant tasting chewable tablets and their production | |
| JPS5959632A (en) | Sustained release composition | |
| JPH037220A (en) | Stable tablets containing alkylcysteine or its acid addition salts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090912 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090912 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100912 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100912 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110912 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110912 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110912 Year of fee payment: 8 |
|
| LAPS | Cancellation because of no payment of annual fees |